Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

5.620 +0.120 (+2.18%)
Streaming Delayed Price Updated: 2:01 PM EDT, Apr 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather... 
Via Benzinga
After Bill Gates Dumps Billions In Berkshire To Buy Microsoft, His Quiet Biotech Portfolio Has Made A New Trade
Bill Gates has two portfolios he makes trades from: the Bill & Melinda Gates Foundation and the Bill & Melinda Gates Foundation Trust. 
Via Benzinga
Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™
From Vir Biotechnology, Inc.
Via GlobeNewswire
Data From Multiple Ongoing Trials Of Vir Biotech's HBV Therapies Show Promising Action
Via Benzinga
Why Vir Biotechnology Jumped Nearly 19% Today
A COVID-19 partnership with a major drugmaker is producing more fruit than expected. 
Via The Motley Fool
Vir Biotech Secures US Government Contract For Influenza & Other Infectious Disease Candidates
Via Benzinga
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
FDA Moves Step Closer For Opioid Overdose Medication Access, Says Certain Naloxone Products Can Potentially Be Used In OTC Setting
Via Benzinga
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection
From Vir Biotechnology, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers 
Via Benzinga
This Hepatitis Stock Has 'Multiple Paths To Value Creation,' Expects To Double, Bullish Analyst Predicts
Via Benzinga
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
Gainers 
Via Benzinga
Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
What 5 Analyst Ratings Have To Say About Vir Biotechnology
Over the past 3 months, 5 analysts have published their opinion on Vir Biotechnology (NASDAQ:VIR) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth
Sales of Vir Biotechnology and GSK's Covid antibody almost tripled sales estimates. 
Via Investor's Business Daily
Block, MasTec, Universal Display And Some Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
From Vir Biotechnology, Inc.
Via GlobeNewswire
Earnings Scheduled For November 3, 2022
Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion. 
Via Benzinga
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022
From Vir Biotechnology, Inc.
Via GlobeNewswire
Boston University's COVID-19 Created In Lab Research Comes Under Scrutiny
Boston University created an artificial form of COVID-19 in a laboratory. Now, U.S. health officials have launched an inquiry into a controversial study. The Boston University research was designed to... 
Via Benzinga
This Addiction Drug Shows Some Potential Against Long COVID Symptoms
Researchers are working on cures for long COVID. With some success, naltrexone has been used to treat pain, fatigue, and brain fog months after a coronavirus infection. 
Via Benzinga
Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A
From Vir Biotechnology, Inc.
Via GlobeNewswire
Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference
From Vir Biotechnology, Inc.
Via GlobeNewswire
The Next Pandemic? Vir Biotechnology Just Signed A $1 Billion Deal To Work On It
BARDA will pay Vir up to $1 billion to develop its experimental treatment. 
Via Investor's Business Daily
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
From Vir Biotechnology, Inc.
Via GlobeNewswire
3 Biotech Stocks to Buy Now for Extraordinary Gains
These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market. 
Via InvestorPlace
WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.